Key Takeaway: What Omnibus CSDDD Really Means for Pharma

The Omnibus proposal can be distilled into a clear regulatory principle:

“Focus on direct suppliers, and only go deeper when risk justifies it.”

At face value, this suggests a more limited, risk-based approach to supply chain due diligence. However, the pharmaceutical sector operates differently from most industries—and that distinction matters.

Why Pharma Is Different

In practice, pharmaceutical companies already go beyond minimum regulatory expectations. Deep supplier oversight is not new—it’s embedded in quality and compliance systems.

This means:

• Companies often go deeper than the law strictly requires
• Multi-tier visibility is already pursued for quality, safety, and regulatory reasons

What Actually Changes

The real impact of the Omnibus CSDDD in pharma is not structural expansion—but formalisation.

• ESG considerations become integrated into existing supplier qualification systems
• Sustainability criteria are layered onto established GMP processes
• Documentation and audit expectations become more explicit and standardized

Importantly:

This is not about building entirely new compliance layers—it’s about upgrading existing ones.

Strategic Implications (Often Overlooked)

While the legal scope may appear narrower, the operational impact extends across the value chain in more subtle ways.

• EU MAHs remain the regulatory anchor
  They carry full legal responsibility and accountability under CSDDD
• Non-EU CMOs and API suppliers remain outside direct legal scope
  They are not directly regulated under the directive

However: